Adial Pharmaceuticals develops AD04, an experimental drug for alcohol use disorder, and is based in Charlottesville, Virginia. ADIL reports earnings on Wed, Nov 18, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 4 | Alliance Global Partners | Initiated | Buy | |
| Jun 15 | LUCID CAPITAL MARKETS | Initiated | Buy |
Seasonality
How ADIL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in ADIL in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ADIL is in one of them and how their past ADIL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ADIL in an article yet. Here's the latest on the wider market.
About Adial Pharmaceuticals
Adial Pharmaceuticals is a drug development company based in Charlottesville, Virginia. It is working to develop AD04, an experimental drug for alcohol use disorder, and it has no products approved for sale yet. Its target patients are people with alcohol use disorder, and the company is focusing its work on those with specific genetic profiles. It aims to meet regulatory requirements mainly in the United States and Europe.
- Headquarters
- Charlottesville, VA